Magnus Nilsson - Xvivo Perfusion CEO and Director
| XVIVO Stock | SEK 467.50 10.00 2.19% |
CEO
Dr. Magnus Nilsson has served as Chief Executive Officer of Xvivo Perfusion AB since 2011. He no longer serves as Member of the Board of Directors of the Company, effective as of May 3, 2016. Before that, he had served as CEO in Vitrolife since 2003. Previously, he was Project Leader for preclinical and clinical development at KaroBio AB and Pharmacia Upjohn AB. He holds a Doctorate of Medical Sciences degree from Uppsala Universitet. since 2016.
| Age | 67 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 46 3 17 88 21 50 |
| Web | https://www.xvivoperfusion.com |
Xvivo Perfusion Management Efficiency
Xvivo Perfusion's management efficiency ratios could be used to measure how well Xvivo Perfusion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Magnus Angermund | Hexatronic Group AB | 55 | |
| Lars Hansen | Invisio Communications AB | 60 | |
Management Performance
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 |
Xvivo Perfusion AB Leadership Team
Elected by the shareholders, the Xvivo Perfusion's board of directors comprises two types of representatives: Xvivo Perfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xvivo. The board's role is to monitor Xvivo Perfusion's management team and ensure that shareholders' interests are well served. Xvivo Perfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xvivo Perfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jaya Tiwari, VP Affairs | ||
| Magnus Nilsson, CEO and Director | ||
| Katrin Gisselfalt, Global Director | ||
| Charlotte Walldal, Global director | ||
| Lena BSc, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Johan Holmstrom, Chief Officer | ||
| Christoffer Rosenblad, Acting Officer | ||
| Christer Flon, Global Head of Marketing and Sales and Global Marketing and Sales Director | ||
| Kristoffer Nordstrom, CFO Relations |
Xvivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xvivo Perfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 5.54 B | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 662.55 X | |||
| Price To Book | 4.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.